Egetis Therapeutics AB Statistics
Want to see SE:EGTX full AI Analyst Report?
Egetis Therapeutics AB (EGTX) Stock Statistics & Valuation Metrics
Total Valuation
Egetis Therapeutics AB has a market cap or net worth of SEK 5.21B. The enterprise value is SEK 3.93B.
- Market Cap
- SEK 5.21B
- Enterprise Value
- SEK 3.93B
Share Statistics
Egetis Therapeutics AB has 464,965,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 464,965,580
- Owned by Insiders
- ―
- Owned by Institutions
- 0.32%
Financial Efficiency
Egetis Therapeutics AB’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -79.16%.
- Return on Equity (ROE)
- -1.01
- Return on Assets (ROA)
- -0.54
- Return on Invested Capital (ROIC)
- -79.16%
- Return on Capital Employed (ROCE)
- -0.87
- Revenue Per Employee
- 1.02M
- Profits Per Employee
- -5.61M
- Employee Count
- 61
- Asset Turnover
- 0.10
- Inventory Turnover
- 21.74
Valuation Ratios
The current PE Ratio of Egetis Therapeutics AB is -10.37. Egetis Therapeutics AB’s PEG ratio is 0.80.
- PE Ratio
- -10.37
- PS Ratio
- 74.18
- PB Ratio
- 15.32
- Price to FCF
- -14.76
- Price to Operating Cash Flow
- -14.81
- PEG Ratio
- 0.80
Income Statement
In the last 12 months, Egetis Therapeutics AB had revenue of 62.40M and earned -342.50M in profits. Earnings per share was -0.93.
- Revenue
- 62.40M
- Gross Profit
- 12.40M
- Operating Income
- -346.90M
- Pretax Income
- -342.10M
- Net Income
- -342.50M
- EBITDA
- -343.20M
- Earnings Per Share (EPS)
- -0.93
Cash Flow
In the last 12 months, operating cash flow was -351.70M and capital expenditures -1.00M, giving a free cash flow of -352.70M billion.
- Operating Cash Flow
- -351.70M
- Free Cash Flow
- -352.70M
- Free Cash Flow per Share
- -0.76
Dividends & Yields
Egetis Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.77%
- Earnings Yield
- -9.03%
Stock Price Statistics
- Beta
- -0.31
- 52-Week Price Change
- 70.99%
- 50-Day Moving Average
- 9.14
- 200-Day Moving Average
- 6.76
- Relative Strength Index (RSI)
- 72.86
- Average Volume (3m)
- 3.07M
Important Dates
Egetis Therapeutics AB upcoming earnings date is Feb 25, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Egetis Therapeutics AB as a current ratio of 1.05, with Debt / Equity ratio of 26.75%
- Current Ratio
- 1.05
- Quick Ratio
- 1.04
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.36
- Interest Coverage Ratio
- -15.28
Taxes
In the past 12 months, Egetis Therapeutics AB has paid 400.00K in taxes.
- Income Tax
- 400.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Egetis Therapeutics AB EV to EBITDA ratio is -11.08, with an EV/FCF ratio of -14.21.
- EV to Sales
- 71.39
- EV to EBITDA
- -11.08
- EV to Free Cash Flow
- -14.21
- EV to Operating Cash Flow
- -14.25
Balance Sheet
Egetis Therapeutics AB has SEK 266.50M in cash and marketable securities with SEK 70.40M in debt, giving a net cash position of SEK 196.10M billion.
- Cash & Marketable Securities
- SEK 266.50M
- Total Debt
- SEK 70.40M
- Net Cash
- SEK 196.10M
- Net Cash Per Share
- SEK 0.42
- Tangible Book Value Per Share
- SEK 0.00
Margins
Gross margin is 13.53%, with operating margin of -650.14%, and net profit margin of -669.66%.
- Gross Margin
- 13.53%
- Operating Margin
- -650.14%
- Pretax Margin
- -669.09%
- Net Profit Margin
- -669.66%
- EBITDA Margin
- -644.44%
- EBIT Margin
- -658.83%
Analyst Forecast
The average price target for Egetis Therapeutics AB is SEK 11.25, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- SEK 11.25
- Price Target Upside
- 0.45% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- 26.71%
- EPS Growth Forecast
- -17.29%
Scores
- Smart Score
- ―
- AI Score
- 52
